{
    "title": "109_s96",
    "content": "The Act may be cited as the \"Flu Vaccine Incentive Act of 2005\" or the \"FLU-VIA\". The findings are outlined in Section 2. The Flu Vaccine Incentive Act of 2005, also known as FLU-VIA, highlights the findings that the production of the influenza vaccine in the United States has decreased to only 2 companies. New technologies are being developed to speed up and reduce costs in vaccine production, such as using cell lines from silk moths. The Act emphasizes the importance of encouraging research and development in this area. The Flu Vaccine Incentive Act of 2005 emphasizes the importance of research and development in influenza vaccine production. It targets appropriated funds for research and development, and eliminates the price cap for purchasing influenza vaccines. The Flu Vaccine Incentive Act of 2005 amends the Vaccines for Children Program to exclude influenza vaccines from price regulations. The Flu Vaccine Incentive Act of 2005 excludes influenza vaccines from price regulations for contracts entered into after the enactment date. It also applies to purchases by Federal agencies under agreements negotiated by the Secretary of Health and Human Services. Incentives for constructing influenza vaccine manufacturing facilities are provided under Section 5 of the Flu Vaccine Incentive Act of 2005. The Flu Vaccine Incentive Act of 2005 provides incentives for constructing influenza vaccine manufacturing facilities, including the influenza vaccine manufacturing facilities investment tax credit of 20 percent of the qualified investment for any taxable year. The Flu Vaccine Incentive Act of 2005 offers a 20% tax credit for qualified investments in influenza vaccine manufacturing facilities. Qualified investment is defined as the basis of property placed in service during the taxable year, meeting specific criteria for use in manufacturing, distribution, or research and development of influenza vaccines. The Flu Vaccine Incentive Act of 2005 provides a 20% tax credit for qualified investments in influenza vaccine manufacturing facilities. Qualified investment is defined as property used for manufacturing, distribution, or research and development of influenza vaccines, complying with relevant regulations. Certain expenditure rules apply, and the provision does not apply to property placed in service after December 31, 2014. Technical amendments are also included. The Flu Vaccine Incentive Act of 2005 offers a 20% tax credit for investments in influenza vaccine manufacturing facilities. Amendments include adding the basis of influenza vaccine manufacturing facilities property to the Internal Revenue Code. The Flu Vaccine Incentive Act of 2005 provides a 20% tax credit for investments in influenza vaccine manufacturing facilities. Section 48 of the Internal Revenue Code is amended to include other credits. The effective date for these amendments is after December 31, 2004."
}